The estimated Net Worth of John Valliant is at least $9.3 Milione dollars as of 25 April 2022. Dr Valliant owns over 8,694 units of Fusion Pharmaceuticals stock worth over $6,856,068 and over the last 4 years he sold FUSN stock worth over $1,599,755. In addition, he makes $845,495 as Founder e CEO & Director at Fusion Pharmaceuticals.
Dr has made over 16 trades of the Fusion Pharmaceuticals stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 8,694 units of FUSN stock worth $52,512 on 25 April 2022.
The largest trade he's ever made was selling 47,502 units of Fusion Pharmaceuticals stock on 15 February 2022 worth over $383,816. On average, Dr trades about 9,718 units every 3 days since 2020. As of 25 April 2022 he still owns at least 318,147 units of Fusion Pharmaceuticals stock.
You can see the complete history of Dr Valliant stock trades at the bottom of the page.
Dr. John F. Valliant is the Founder, CEO & Director at Fusion Pharmaceuticals.
As the Founder e CEO & Director of Fusion Pharmaceuticals, the total compensation of Dr Valliant at Fusion Pharmaceuticals is $845,495. There are no executives at Fusion Pharmaceuticals getting paid more.
Dr Valliant is 51, he's been the Founder e CEO & Director of Fusion Pharmaceuticals since . There are 4 older and 2 younger executives at Fusion Pharmaceuticals. The oldest executive at Fusion Pharmaceuticals Inc. is Dr. James J. O'Leary, 56, who is the Chief Medical Officer.
John's mailing address filed with the SEC is C/O FUSION PHARMACEUTICALS INC., TWO INTERNATIONAL PLACE, SUITE 2310, BOSTON, MA, 02110.
Over the last 4 years, insiders at Fusion Pharmaceuticals have traded over $1,703,181 worth of Fusion Pharmaceuticals stock and bought 2,415,900 units worth $40,298,362 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Street Partners Llc Adams e & Johnson Johnson & Johnson.... On average, Fusion Pharmaceuticals executives and independent directors trade stock every 28 days with the average trade being worth of $2,030,355. The most recent stock trade was executed by Steven Gannon on 11 August 2022, trading 44,400 units of FUSN stock currently worth $90,132.
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
Fusion Pharmaceuticals executives and other stock owners filed with the SEC include: